1 Department of Pediatric Respiratory, Wuxi Children's Hospital, Wuxi, China.
2 Department of Pediatrics Laboratory, Wuxi Children's Hospital, Wuxi, China.
Int J Immunopathol Pharmacol. 2018 Jan-Dec;32:2058738418804095. doi: 10.1177/2058738418804095.
Allergies to various environmental factors, in particular mite species, represent a considerable healthcare burden with lost productivity resulting from symptoms including asthma, conjunctivitis, rhinitis, and atopic dermatitis. The complexity of mite species and the allergens that they produce complicates diagnosis and treatment; however, the advent of recombinant DNA technologies now allows clinicians to better pinpoint the specific sensitizing agents and creates new opportunities for avoidance or immunotherapy. Here we discuss the advantages and disadvantages of traditional and novel diagnostic and therapeutic platforms, with particular consideration given to multiplex tests able to generate patient-specific allergen profiles. Immunotherapies tailored to such profiles may be safer and more effective than generalized treatments, but many hurdles, including the costs associated with identifying the protein or protein combinations able to exert the safest and most beneficial effects, must be overcome before such therapies can be globally applied.
对各种环境因素(尤其是螨种)的过敏反应给医疗保健带来了相当大的负担,导致生产力下降,出现哮喘、结膜炎、鼻炎和特应性皮炎等症状。螨种和它们产生的过敏原的复杂性使诊断和治疗变得复杂;然而,重组 DNA 技术的出现使临床医生能够更好地确定特定的致敏剂,并为避免或免疫治疗创造了新的机会。在这里,我们讨论了传统和新型诊断和治疗平台的优缺点,并特别考虑了能够生成患者特异性过敏原谱的多重测试。针对这些图谱量身定制的免疫疗法可能比常规治疗更安全、更有效,但在这些疗法能够在全球范围内应用之前,还必须克服许多障碍,包括确定能够产生最安全和最有益效果的蛋白质或蛋白质组合相关的成本。